- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01956487
Bioequivalence of RYTHMOL SR® Manufactured at Two Different Sites
June 9, 2017 updated by: GlaxoSmithKline
A Phase 1, Open-Label, Crossover Study to Demonstrate the Bioequivalence of RYTHMOL SR® (Propafenone Hydrochloride) Manufactured at Two Different Sites
Bioequivalence of propafenone hydrochloride capsules manufactured at two different sites
Study Overview
Detailed Description
This will be a Phase 1, randomized, open-label, single-dose, three-period, crossover study to assess the bioequivalence of propafenone hydrochloride manufactured at two different sites in healthy adult volunteers.
Approximately 36 subjects will receive a 3 single doses of propafenone hydrochloride 425mg, each administered separately, in the fasted state with a 7 day washout period between doses.
Propafenone hydrochloride is an antiarrhythmic indicated to prolong the time to recurrence of symptomatic atrial fibrillation in patients with episodic (most likely paroxysmal or persistent) atrial fibrillation who do not have structural heart disease.
A follow-up visit will occur 7-10 days after the final dose of study drug.
Study Type
Interventional
Enrollment (Actual)
38
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21225
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female between 18 and 55 years of age inclusive, at the time of signing the informed consent.
- Body weight greater than or equal to 50kg and BMI within the range 18.5 - 31.0kg/m2 (inclusive).
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
- AST, ALT, alkaline phosphatase and bilirubin less than or equal to 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- A female subject is eligible to participate if she postmenopausal or on a stable regimine of an approved contracetive
- Capable of giving written informed consent,
Exclusion Criteria:
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- A positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
- A positive test for HIV antibody.
- History of regular alcohol consumption within 6 months of the study defined as:an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12g of alcohol: 12 ounces (360ml) of beer, 5 ounces (150ml) of wine or 1.5 ounces (45ml) of 80 proof distilled spirits.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: either 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- The subject has donated blood or blood products in excess of 500mL within a 56 day period.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
- Lactating females.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Subject is mentally or legally incapacitated.
- History of sensitivity to heparin or heparin-induced thrombocytopenia.
- Urinary cotinine levels indicative of smoking or history of regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
- Consumption of red wine, seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose of study medication.
- Unwilling to abstain from alcohol for 48 hours prior to screening and 48 hours prior to the start of dosing until collection of the final pharmacokinetic sample during each treatment period.
- Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs. Subjects with a history of cholecystectomy, peptic ulceration, inflammatory bowel disease or pancreatitis should be excluded.
- The subject's systolic blood pressure is outside the range of 90-140 mmHg, or diastolic blood pressure is outside the range of 45-90mmHg or heart rate is outside the range of 55-100bpm for female subjects or 50-100bpm for male subjects.
- Screening ECG within normal limts for age and gender
- Evidence of previous myocardial infarction.
- Any conduction abnormality (including but not specific to left or right complete bundle branch block, AV block [2nd degree or higher], Wolf Parkinson White [WPW] syndrome, non-sustained or sustained ventricular tachycardia (3 or more consecutive ventricular ectopic beats), sinus pauses > 3 seconds, or other significant arrhythmia which, in the opinion of the principal investigator and GSK medical monitor, will interfere
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Propafenone
Open label comparison of 2 formulations
|
Comparison of drug from 2 manufacturing sites
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bioequvalence
Time Frame: 48 hours
|
Two formulations of propafenone hydrochloride
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics
Time Frame: 48 hours
|
Plasma AUC and Cmax of propafenone
|
48 hours
|
Adverse events
Time Frame: 48 hours
|
Safety and Tolerability
|
48 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- "RYTHMOL is a registered trademark of G. Petrik used under license by Abbott Laboratories."
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 11, 2012
Primary Completion (Actual)
June 27, 2012
Study Completion (Actual)
June 27, 2012
Study Registration Dates
First Submitted
July 19, 2012
First Submitted That Met QC Criteria
October 4, 2013
First Posted (Estimate)
October 8, 2013
Study Record Updates
Last Update Posted (Actual)
June 12, 2017
Last Update Submitted That Met QC Criteria
June 9, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 116371
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study Data/Documents
-
Dataset Specification
Information identifier: 116371Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 116371Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: 116371Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 116371Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 116371Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 116371Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 116371Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arrhythmia, Cardiac
-
Medical University of LodzNot yet recruitingCardiac Arrhythmia | Supraventricular ArrhythmiaPoland
-
Myant Medical Corp.Partners in Advanced Cardiac EvaluationCompleted
-
New York Institute of TechnologyCompleted
-
Kansas City Heart Rhythm InstituteBiosense Webster, Inc.TerminatedArrhythmia, CardiacUnited States
-
Children's National Research InstituteNational Institutes of Health (NIH)CompletedVentricular Tachycardia | Cardiac ArrhythmiaUnited States
-
SanofiCompletedVentricular Arrhythmia | Arrhythmia ProphylaxisNetherlands, Spain, Belgium, Japan, Finland, Chile, Australia, United States, Argentina, Canada, Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, Mexico, Norway, Poland, Portugal, Russian Federation, Slovakia, South Africa and more
-
Ruiqin xieCompletedSlow Arrhythmia; Left Bundle Branch Pacing; Cardiac FunctionChina
-
Adana City Training and Research HospitalCompleted
-
University of California, San DiegoCompletedAtrioventricular Block | Cardiac Arrhythmia | Sick Sinus Syndrome | Symptomatic BradycardiaUnited States
-
Huawei Device Co., LtdRecruiting
Clinical Trials on Propafenone
-
Vanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI)Terminated
-
Valduce HospitalCompletedAtrial FibrillationItaly
-
Ultragenyx Pharmaceutical IncNovartis; Mereo BioPharmaWithdrawnChronic-kidney Disease Stage 5D on Stable Hemodialysis
-
Shandong UniversityRecruiting
-
Yong Seog OhUnknown
-
University of PennsylvaniaCompletedAtrial FibrillationUnited States
-
Ospedale San DonatoUnknownVentricular Tachycardia | Ventricular Premature ComplexesItaly
-
Jason AndradeMedtronic; Ottawa Heart Institute Research Corporation; Baylis Medical CompanyActive, not recruitingAtrial FibrillationCanada
-
Samsung Medical CenterCompletedAtrial FibrillationKorea, Republic of
-
University Hospital, GhentCompleted